TEM

4 - Tempus AI, Inc. (0001717115) (Issuer)

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that the company will host an Investor Day on Friday, May 29, 2026. The event will start at 8:00 a.m. CT / 9:00 a.m. ET and will feature Tempus' leadership team, including, Founder and CEO Eric Lefkofsky, Chief Financial Officer Jim Rogers, CEO of Data and Applications Ryan Fukushima, CEO of Diagnostics Tom Schoenherr, and Chief Scientific Officer Kate Sasser, PhD. The program will include presentations from the company's Diagnostics and Data & Applications organizations. A live webcast of the event can be accessed through this link. For those unable to tune into th

144 - Tempus AI, Inc. (0001717115) (Subject)

Tempus AI, Inc. (NASDAQ:TEM), a technology company advancing precision medicine through the practical application of artificial intelligence, today announced it has been named to TIME's 10 Most Influential Health and Life Science Companies of 2026. The inaugural TIME100 Companies: Industry Leaders list, an expansion of the TIME100 Most Influential Companies issue, recognizes organizations shaping the future of their sectors through extraordinary impact and innovation. Tempus was recognized for its leadership in bridging the gap between data and technology to make genomic testing and clinical analysis more intelligent for patients. In naming Tempus to its list of the most influential compa

eyonis® LCS 510(k) clearance sets stage for commercialization in the United States New leadership of U.S. subsidiary and collaboration with Tempus accelerate rollout 28% reduction in operating loss in 2025 year‑over‑year, demonstrating strengthened cost discipline and operational efficiency iCRO order backlog reaches a new record at €79.8 million as of March 31, 2026 Cash and cash equivalents of €14.0 million as of March 31, 2026 Cash runway through year‑end 2026, with potential for further extension subject to the exercise of 2025 warrants, representing up to €44.4 million in additional proceeds Regulatory News: Median Technologies (FR0011049824, ALMDT, "Median" or the

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, and the Keck School of Medicine of USC and Keck Medicine of USC, today announced a multi-faceted collaboration aimed at transforming patient care and accelerating research through the power of data and AI. This collaboration is designed to transform care delivery across more than 1.5 million annual patient visits to the USC Norris Comprehensive Cancer Center, the Keck Hospital of USC, USC Verdugo Hills and all USC-affiliated hospitals and clinics across Southern California. The collaboration is built on four foundational pillars, co-created to drive clinical impact, research scale,

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the first quarter ended March 31, 2026 on Tuesday, May 5, 2026. The company will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the results and provide a business update. The call will be led by Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the "Events" section of the Tempus Investor Relations website. For those unable to listen to the live broadcast, a recording will be available on the website following the call. Alt

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, and Predicta Biosciences, a precision oncology company developing novel diagnostic solutions for deep molecular characterization of hematologic malignancies with a focus on circulating tumor cells, today announced the commercial expansion of a co-branded whole-genome sequencing (WGS) assay, currently known as GenoPredicta™, intended for the comprehensive genomic characterization of hematologic malignancies and measurable residual disease (MRD) monitoring. GenoPredicta is an ultrasensitive assay that extracts deep genetic insights from peripheral blood or bone marrow. By integrating

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acceptance of 31 abstracts—including one oral presentation—for the American Association for Cancer Research (AACR) Annual Meeting 2026 taking place April 17–22 in San Diego. "The research that Tempus is presenting at this year's AACR annual meeting underscores the scale and real-world impact of Tempus' multimodal dataset and AI-enabled diagnostic solutions," said Kate Sasser, PhD, Chief Scientific Officer at Tempus. "Across these studies, our researchers are uncovering clinically relevant insights that not only deepen our understanding of tumor biology, but also

Jefferies initiated coverage of Tempus AI with a rating of Underperform and set a new price target of $35.00

TD Cowen upgraded Tempus AI from Hold to Buy and set a new price target of $65.00

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of an automated clinical update service designed to support guideline-concordant care by placing patients on an "active follow-up" track. This integrated workflow provides clinicians with ongoing therapy monitoring and context-aware notifications seamlessly delivered through Hub, Tempus' secure, AI-enabled physician portal. Because NCCN guidelines, FDA approvals, and patient context can all evolve rapidly, an initial genomic report can quickly become outdated relative to a patient's ongoing treatment journey. Tempus is addressing this challenge by automat

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced an expanded, multi-year collaboration with Gilead Sciences, Inc. (NASDAQ:GILD) aimed at building and advancing Gilead's oncology pipeline. To date, Gilead has leveraged Tempus' extensive repository of de-identified multimodal data to inform a range of oncology R&D initiatives, including trial design, indication selection, biomarker strategy, health outcomes analysis and clinical real world evidence. The expanded agreement provides Gilead with enterprise-wide access to Tempus' AI-driven Lens platform, unlocking access to broader datasets across multiple indications a

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, will present at the 25th Annual Needham Virtual Healthcare Conference, taking place April 13-16. Tempus' Chief Financial Officer Jim Rogers, will participate in a fireside discussion at the conference on Tuesday, April 14 at 11:45 am ET. A live webcast of the conversation will be available here. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provid

DEFA14A - Tempus AI, Inc. (0001717115) (Filer)

DEF 14A - Tempus AI, Inc. (0001717115) (Filer)

ALERT is the largest known multicenter, cluster-randomized trial to date evaluating an automated EHR-based notification system designed to address the undertreatment of significant valvular heart disease and accelerate time to treatment. Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from the ALERT (Addressing undertreatment and heaLth Equity in aortic stenosis and mitral regurgitation using an integrated ehR plaTform) trial, which were recently presented at the American College of Cardiology's 75th Annual Scientific Session & Expo. The study, conducted in collaboration with Medtronic, found that automat

DENVER, March 30, 2026 (GLOBE NEWSWIRE) -- Cathie Wood and ARK Invest are making a decisive pivot that signals where the next phase of artificial intelligence value creation may emerge: healthcare. In a series of trades during late March, Wood aggressively reduced exposure to mega-cap technology and semiconductor names while building a high-conviction position in Tempus AI (NASDAQ:TEM). The move reflects a broader thesis she has increasingly emphasized, the most underestimated frontier for AI innovation is healthcare. As AI infrastructure becomes crowded and capital-intensive, ARK is rotating toward companies applying AI to real-world, high-stakes problems like disease detection, drug deve

4 - Tempus AI, Inc. (0001717115) (Issuer)

SCHEDULE 13G/A - Tempus AI, Inc. (0001717115) (Subject)

144 - Tempus AI, Inc. (0001717115) (Subject)

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, and Blood Cancer United® (formerly The Leukemia & Lymphoma Society), the largest global nonprofit focused on blood cancer patient support, research, and advocacy, today announced a strategic collaboration to develop a comprehensive, patient-centered, real-world registry for pediatric acute myeloid leukemia (pAML), a rare and aggressive blood cancer. Part of the Blood Cancer United Dare to Dream Project, the collaboration serves a dual purpose: empowering patients with their health-related data and information relevant to their journey and fueling broader scientific breakthroughs.

DENVER, March 16, 2026 (GLOBE NEWSWIRE) -- When Jensen Huang talks about the future of technology, markets tend to listen. After leading NVIDIA (NASDAQ:NVDA) to become one of the most valuable companies in the world during the AI boom, Huang is now pointing to the next technological wave: digital biology. As he recently put it, "Where do I think that the next amazing revolution is going to come? And this is going to be flat-out one of the biggest ones ever… And there's no question that digital biology is going to be it." For Huang, the idea is simple but profound. Biology is becoming programmable. Instead of treating biology as a slow-moving experimental science, artificial intelligence

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the publication of a new study in JCO Precision Oncology highlighting how advanced features of comprehensive genomic profiling (CGP) expand treatment options for cancer patients in community oncology settings. The study, conducted in collaboration with The Oncology Institute (TOI), reveals that features such as tumor-normal matched sequencing, RNA sequencing, and liquid biopsy reflex identify actionable findings that are missed by more limited standard in-network testing. While organizations like ASCO® and the NCCN® strongly advocate for CGP to guide precision thera

SCHEDULE 13G - Tempus AI, Inc. (0001717115) (Subject)